Advanced Virology
Advanced Virology specializes in high-fidelity production and engineering of research-grade virus stocks using reverse genetics. The company supports customizable solutions across a broad range of viral families—including wild-type, chimeric, and reporter-expressing viruses. Comprehensive quality assurance and documentation protocols are applied to each batch. Custom services enable the development of tailored virus variants, molecular tags, and reporters to meet research and assay needs.
Industries
Nr. of Employees
small (1-50)
Advanced Virology
Advanced Virology is currently seeking investment
Advanced Virology is seeking a investment in the range of 1m-5m
Products
Human norovirus genomic materials and virus stocks (various genotypes and strains) available for research purposes. Offered as wild-type or genomic material, primarily for foundational virology studies and assay development.
Chimeric BSL-2 compatible alphavirus strains generated by combining proteins from different viruses, offered as wild-type or engineered to express fluorescent/luminescent reporters.
Wild-type Sindbis virus and variants engineered to express reporters (eGFP, nLuc, etc.) at high levels. Produced by direct transfection into BHK cells without serial passage and available in multiple formats.
Chimeric alphavirus containing Sindbis virus non-structural proteins and EEEV FL93-939 structural proteins, expressing nanoluciferase at high levels via protease-mediated release, with minimal impact on replication or virulence.
Human norovirus genomic materials and virus stocks (various genotypes and strains) available for research purposes. Offered as wild-type or genomic material, primarily for foundational virology studies and assay development.
Chimeric BSL-2 compatible alphavirus strains generated by combining proteins from different viruses, offered as wild-type or engineered to express fluorescent/luminescent reporters.
Wild-type Sindbis virus and variants engineered to express reporters (eGFP, nLuc, etc.) at high levels. Produced by direct transfection into BHK cells without serial passage and available in multiple formats.
Chimeric alphavirus containing Sindbis virus non-structural proteins and EEEV FL93-939 structural proteins, expressing nanoluciferase at high levels via protease-mediated release, with minimal impact on replication or virulence.
Services
Design and manufacturing of virus strains, including wild-type, chimeric, and molecularly tagged or reporter-expressing viruses and viral genomic material; batch documentation and flexible order sizes are supported.
Design and manufacturing of virus strains, including wild-type, chimeric, and molecularly tagged or reporter-expressing viruses and viral genomic material; batch documentation and flexible order sizes are supported.
Expertise Areas
- Virus stock production
- Custom virus engineering
- Reverse genetics
- Reporter and molecular tag virus construction
Key Technologies
- Reverse genetics systems
- Next-generation sequencing
- Plaque assay
- qPCR
Key People
News & Updates
Advanced Virology will be present at the ASV 2025 annual meeting in Montréal, July 14–17, 2025, to connect with the virology research and biotech community and discuss scalable virus production and custom R&D solutions.
In virology, reproducibility is the bedrock of discovery. Whether developing vaccines, testing antivirals, or building diagnostic assays, success depends heavily on the fidelity of the virus stocks used during R&D. For decades, virus stock production has relied on seed lot systems which use serial passaging to create multiple virus batches from a master seed bank. However, advances in molecular biology now present a clear opportunity to standardize these critical reagents and significantly improve research outcomes and the efficiency and cost-effectiveness of R&D.
Antiviral drug discovery is a cornerstone of modern infectious disease research. Rapid screening of compound libraries and accurate quantitation of virus replication are essential for identifying compounds with potential antiviral effects. One technological development that has enabled fast and scalable screening of large compound libraries is the development of reporter protein–expressing viruses.
Since the establishment of virology over a century ago, serial passaging of virus stocks has been used to study viruses and develop products such as vaccines for medical use. However, in recent decades, the development of reverse genetics-based virus production methodologies has transformed the study of viruses. These methods allow scientists to engineer and reconstitute virus stocks directly from genetic sequences. Consequently, the field of virology is decisively shifting, where possible, towards using reverse genetics for the fundamental task of creating virus stocks for all downstream uses such as R&D, product manufacturing and QC testing.
Advanced Virology will be present at the ASV 2025 annual meeting in Montréal, July 14–17, 2025, to connect with the virology research and biotech community and discuss scalable virus production and custom R&D solutions.
In virology, reproducibility is the bedrock of discovery. Whether developing vaccines, testing antivirals, or building diagnostic assays, success depends heavily on the fidelity of the virus stocks used during R&D. For decades, virus stock production has relied on seed lot systems which use serial passaging to create multiple virus batches from a master seed bank. However, advances in molecular biology now present a clear opportunity to standardize these critical reagents and significantly improve research outcomes and the efficiency and cost-effectiveness of R&D.
Antiviral drug discovery is a cornerstone of modern infectious disease research. Rapid screening of compound libraries and accurate quantitation of virus replication are essential for identifying compounds with potential antiviral effects. One technological development that has enabled fast and scalable screening of large compound libraries is the development of reporter protein–expressing viruses.
Since the establishment of virology over a century ago, serial passaging of virus stocks has been used to study viruses and develop products such as vaccines for medical use. However, in recent decades, the development of reverse genetics-based virus production methodologies has transformed the study of viruses. These methods allow scientists to engineer and reconstitute virus stocks directly from genetic sequences. Consequently, the field of virology is decisively shifting, where possible, towards using reverse genetics for the fundamental task of creating virus stocks for all downstream uses such as R&D, product manufacturing and QC testing.